Oxford researcher Adrian Hill has been awarded the European Inventor Award for his work on R21/Matrix-M, the first highly effective malaria vaccine. With 75-80% efficacy, the vaccine is currently being deployed across a dozen countries, with tens of millions of doses already administered to combat the world’s deadliest infectious disease.
Developing the R21/Matrix-M Vaccine at the Jenner Institute
Adrian Hill, who directs the Jenner Institute at the University of Oxford, led the team responsible for creating R21/Matrix-M. The vaccine represents a scientific milestone, as it is the first to achieve high efficacy against a parasitic disease. Scientists have long struggled to develop such a treatment, largely due to the complexity of the malaria parasite compared to viral pathogens.
“Non c’è mai stato un vaccino contro un parassita. È una scala migliaia di volte più grande dei virus. Il Covid ha 12 geni, il parassita della malaria ne ha 5.000. Bisognava capire quale parte colpire.”
Adrian Hill, Director of the Jenner Institute, via Corriere
According to reporting from Corriere, the parasite’s lifecycle makes it a difficult target. When an infected female Anopheles mosquito bites a human, the parasite enters the bloodstream and reaches the liver within minutes, multiplying rapidly. The parasite then changes its antigenic composition, complicating the immune system’s ability to recognize and neutralize it.
Global Distribution and Production via Serum Institute
The R21/Matrix-M vaccine is manufactured in India by the Open, identified as the world’s largest vaccine producer. At a cost of 3 euros per dose, the vaccine has seen significant uptake, with tens of millions of doses distributed across a dozen countries. Hill emphasizes that the vaccine is part of a broader, concerted public health strategy that includes the use of insecticide-treated nets, spray campaigns, and sustained funding.
The development process relied heavily on international cooperation. Hill specifically credited African medical teams who conducted essential studies in Burkina Faso, Mali, Kenya, and Tanzania, noting that these contributions were vital to the vaccine’s success.
Historical Context and Future Aspirations
Malaria remains the world’s most severe infectious disease, causing hundreds of thousands of deaths annually, the majority of which are children under the age of five. For Hill, the mission is personal, rooted in his early experiences visiting a missionary uncle in Zimbabwe and working as a young doctor in The Gambia, where he witnessed the severe impact of the disease firsthand.
“Posso vedere il reparto della malaria? Com’è oggi?”
Adrian Hill, recalling his future retirement plans, via Open
Reflecting on his career, Hill shared a vision for his eventual retirement: returning to the hospital in The Gambia where he once treated children suffering from malaria. He hopes to ask the nursing staff about the status of the malaria ward and receive the answer: Mi dispiace, professore, qui non vediamo più casi di malaria
.